Cancer and the NDIS: What It Funds and What It Doesn’t

Cancer and the NDIS: where the line actually sits

The short answer is that the NDIS does not fund cancer treatment, and a cancer diagnosis does not make somebody an NDIS participant.

The long answer is more useful, because almost nobody gets caught out by the short version. What catches people out is the territory either side of it: the participant who already has a plan and then gets cancer, and the person left with permanent impairment after cancer treatment who has no idea the scheme might apply to them.

Both of those situations are poorly handled by both systems, and the reason is structural. Cancer Council Australia’s own policy priorities include clarifying roles between health and disability supports, and note that eligibility for additional support is hard to determine without a clear prognosis, and that a cancer diagnosis and hospitalisation can disrupt existing disability supports. When the national peak cancer body lists “work out whose job this is” as a policy priority, you are looking at an unresolved boundary, not a clear rule somebody failed to read.

We are an NDIS provider in New South Wales. We do not treat cancer, we are not a health service, and nothing in this guide is medical advice. What we can speak to is the disability funding side, because it is what we work in every day. For cancer information, Cancer Council’s 13 11 20 is free and answered by cancer nurses.

The principle, stated properly

The NDIS funds disability supports arising from permanent impairment. The health system funds treatment of health conditions. That division is set out in the applied principles that govern how the NDIS interfaces with mainstream services, and it is the reason cancer sits outside the scheme.

The NDIA’s own guidance for GPs sets out three points that do most of the work here:

One: access does not depend on how the impairment arose. The scheme does not ask what caused your impairment. It asks whether the impairment meets the criteria. This is the most important sentence in the whole area and it is the one most often got wrong — including by clinicians, who sometimes tell patients that cancer-caused impairment “isn’t an NDIS thing”.

Two: time-limited conditions are excluded. The NDIS requires impairment that is permanent, or likely to be permanent. A condition that is expected to resolve, or that is being actively treated with the expectation of resolution, does not meet that test.

Three: chronic health conditions unrelated to a person’s disability are excluded, and the NDIS does not fund medication or medical care for treating a chronic condition. But — and the guidance says this explicitly — disability supports may still be available where a health condition causes a disability, giving the example of amputation.

Put those three together and the cancer position falls out:

• Active cancer under treatment: not an NDIS matter. It is a health condition being treated, with an expected trajectory. Health system.
• Cancer treatment itself — surgery, chemotherapy, radiotherapy, immunotherapy, medications, hospital stays, oncology appointments, palliative medical care: health system. Medicare, the public hospital system, the Pharmaceutical Benefits Scheme.
• Permanent impairment caused by cancer or by its treatment: potentially an NDIS matter, assessed on the impairment, not the cause.

That last line is where the real content is, and it is the one almost nobody is told.

Cancer is not on List A or List B

Worth clearing up, because people look.

The NDIS publishes two lists. List A is conditions where permanent impairment with substantially reduced functional capacity is taken as given — things like moderate to profound intellectual disability, autism at Level 2 or 3, cerebral palsy at GMFCS level 3, 4 or 5, permanent blindness in both eyes, deafblindness, and amputation or congenital absence of two limbs. List B is conditions where permanence is likely but functional capacity still has to be assessed — it includes the neurological conditions most people in this field would recognise, such as multiple sclerosis, motor neurone disease, Huntington’s disease and several dementias.

Cancer appears on neither list. Not as a category, and not as any specific cancer.

That is not a bar to access. Lists A and B are shortcuts, not gates — most participants do not enter the scheme through them. It does mean that a cancer-related application has to be built on evidence of the impairment and its permanence from the ground up, which is more work and is the reason these applications often fail at the first attempt.

What permanent impairment after cancer actually looks like

This is the category people miss, so it is worth being specific. There is a separate guide in this library on it in detail; here is the shape of it.

Cancer and cancer treatment can leave impairment that is unambiguously permanent, including:

• Amputation. The NDIA’s own guidance uses amputation as its example of a health condition causing disability. A limb amputated for a bone or soft tissue sarcoma is permanent in exactly the way an amputation from any other cause is permanent.
• Brain tumour effects. Cognitive, physical, communication, visual or behavioural impairment from a tumour or from its surgical and radiotherapy treatment. This is the clearest cancer–NDIS intersection and it has its own guide here.
• Spinal cord damage from a tumour or from surgery, producing paraplegia or tetraplegia — which is on List A when caused by spinal cord or brain injury.
• Permanent peripheral neuropathy from chemotherapy, which can cause lasting loss of sensation, balance problems and loss of fine motor function.
• Lymphoedema after lymph node removal or radiotherapy, which is a chronic, progressive condition requiring lifelong management.
• Permanent stoma following bowel or bladder surgery.
• Laryngectomy and permanent loss of voice.
• Permanent hearing loss from platinum-based chemotherapy or radiotherapy to the head.
• Late effects of childhood cancer treatment, which can include cognitive impairment, endocrine problems, cardiac damage and growth effects, appearing years after treatment finished.

None of these are “cancer”. All of them are impairments, assessed on their own terms.

For an existing participant who gets cancer

This is the more common situation and the one where the system behaves worst. There is a full guide to it in this library; the funding position in summary:

What stays with the health system: all treatment, all cancer medications, oncology appointments, hospital admissions, radiotherapy, chemotherapy, surgery, and medical palliative care.

What stays with the NDIS: the person’s existing disability supports. Daily living assistance, personal care, community participation, supported independent living, assistive technology, allied health that relates to their disability, support coordination. Those do not stop because a cancer diagnosis has happened.

Where it gets genuinely messy:

• Support while in hospital. The health system’s position is that hospitals provide care to inpatients. The NDIS does not generally duplicate that. But a person with communication disability, or high behaviour support needs, or who needs a familiar worker to eat safely, may be unsafe in hospital without their usual support. In practice this gets negotiated case by case, and whether a participant’s worker can attend in hospital depends on the plan, the hospital and who is willing to argue.
• Increased need caused by treatment. Treatment side effects — fatigue, neuropathy, weakness, nausea — can substantially increase somebody’s support needs for months. Their plan reflects the person they were at the last planning meeting. A plan reassessment or a plan variation is the mechanism, and it takes time that treatment schedules do not allow for.
• SIL arrangements during a long admission. Whether a SIL place is held, and what is charged, during an extended hospital stay is an arrangement-specific question that is better settled in writing before it happens than argued afterwards.
• Discharge. A person who needs more support at home than they did before, or who needs home modifications, or who cannot go back to where they were living, is in the hospital discharge territory the NDIS calls medium term accommodation and specialist disability accommodation. The NDIA’s position for participants in hospital is that where somebody is eligible for specialist disability accommodation, supported independent living, individualised living options or home modifications, a confirmed long-term home is not a prerequisite for discharge support. That matters, because discharge planning sometimes proceeds on the assumption that it is.

Cancer Council’s policy work identifies this disruption explicitly, and also notes that eligibility for additional support is hard to determine without a clear prognosis. That is the crux. Disability funding systems are built around stable, permanent need. Cancer produces changing, uncertain need, sometimes over short periods, with a prognosis nobody will commit to. The two models do not fit together, and the person is in the gap while everybody works it out.

The age 65 problem, which is the harshest part

This is the part of the cancer–NDIS relationship with the biggest financial consequence, and it hits people who have done nothing wrong.

You cannot join the NDIS after you turn 65. The age test applies at the point of application, not at the point of diagnosis or of impairment.

So consider two people with the same impairment — say, an above-knee amputation following a sarcoma, with the same functional consequences.

The first is 62 when they apply. If they meet the access criteria, they are a participant, and the scheme funds reasonable and necessary disability supports for the rest of their life, with no means testing of the supports themselves and no hard annual ceiling — plans are built on assessed need.

The second is 66 when they apply. They are ineligible on age, regardless of how severe the impairment is or how clearly it meets every other criterion. Their pathway is the aged care system: Support at Home, which replaced Home Care Packages on 1 November 2025. The highest classification is capped at roughly $108,000 a year — around $78,000 in ongoing support, plus up to about $15,000 for assistive technology and up to about $15,000 for home modifications. It is means tested, with co-contributions depending on income and assets.

That is a large and permanent difference in both the amount available and the way it is assessed, and it turns on which side of a birthday the application landed.

Why this matters specifically for cancer: cancer incidence rises steeply with age. The permanent impairments that cancer treatment causes — amputations, neuropathy, lymphoedema, stomas, cognitive effects from brain tumour treatment — disproportionately arise in people over 60. A substantial share of the people who acquire NDIS-type impairment through cancer acquire it at an age where the scheme is closed to them.

The practical implication. If somebody is approaching 65 and has permanent impairment from cancer or its treatment that might meet the access criteria, the application should be lodged before the birthday, even if the evidence is not perfect and even if the situation is still changing. An application lodged at 64 and decided at 65 is still an application made at 64. One lodged at 65 and a month is not an application at all.

For people over 65, the pathway is My Aged Care on 1800 200 422. It is a different system with different rules and it is worth engaging with properly rather than treating as a consolation prize.

The permanence problem, and how applications actually get built

The hardest part of a cancer-related NDIS application is permanence, because cancer is a condition with a trajectory and the NDIS wants impairment that is settled.

What that means in practice:

Separate the impairment from the cancer in the evidence. The application is not about the cancer. It is about the amputation, the neuropathy, the cognitive impairment, the lymphoedema. Evidence that reads as “this person has cancer and needs help” invites a refusal on the basis that cancer is a health condition. Evidence that reads as “this person has permanent loss of function in both hands from chemotherapy-induced neuropathy, documented over eighteen months, with no expectation of further recovery” is an impairment application.

Get the word “permanent” from the right person, in writing. For neuropathy, the oncologist or a neurologist. For amputation, the surgeon or rehabilitation physician. For brain tumour effects, the neurosurgeon, neurologist or neuropsychologist. For lymphoedema, the treating specialist or lymphoedema therapist. A GP letter helps, but a specialist statement that the impairment is permanent and that available treatment has been tried carries much more weight.

Document functional impact, not diagnosis. The NDIS access test is about substantially reduced functional capacity in communication, social interaction, learning, mobility, self-care or self-management. An occupational therapy functional assessment is usually the most useful single document, because it translates impairment into the language the scheme actually assesses.

Expect to wait until things have stabilised — but not forever. Applying during active treatment, when recovery is still expected, usually fails. Applying two years after treatment finished, with documented plateau, usually works better. The exception is the age 65 line, which overrides this entirely: if the birthday is coming, apply.

Know the review pathways. If access is refused, there is an internal review, requested within three months of the decision, which the NDIA must decide within 90 days. If that fails, the Administrative Review Tribunal — which replaced the Administrative Appeals Tribunal in October 2024 — hears NDIS matters. There is no application fee, and free advocacy support is available through the NDIS Appeals programme. First-attempt refusals on cancer-related impairment are common and should not be treated as final.

The brain tumour episode, which shows how unsettled this is

There is a worked example of how contested this boundary is, and it is recent.

Around the middle of 2023, advocates working with people affected by brain cancer reported a sudden and sharp change in how the NDIA was reviewing brain tumour access applications nationally. Applications that would previously have succeeded were being treated differently. It took roughly ten months of advocacy, including engagement with the then NDIS Minister, before applications were reported as being approved nationally again. The reporting on this came from brain cancer advocacy organisations rather than from published NDIA policy, which is itself part of the point — the shift was not announced, and it was not visible until people started being refused.

The relevant lesson is not about brain tumours specifically. It is that the application of the permanence test to cancer-related impairment is a matter of internal interpretation, that interpretation has changed without notice before, and the evidence bar in this area is high enough that it responds to how carefully an application is built. A cancer-related application needs the treating team’s active involvement, not a form filled in by a family member.

What the NDIS will not fund, plainly

To save people from asking:

• Chemotherapy, radiotherapy, immunotherapy, surgery, or any cancer treatment.
• Cancer medications, including PBS and non-PBS drugs.
• Oncology, haematology, surgical or radiation oncology appointments.
• Hospital admissions and inpatient care.
• Scans, biopsies, pathology or diagnostic tests.
• Medical palliative care, including specialist palliative medical and nursing care.
• Wigs, scalp cooling, or other treatment-related items — these generally sit with the health system or with cancer support organisations.
• Transport to cancer treatment, as a general rule, although where a participant has funded transport in their plan the position is less clear-cut and worth checking.
• Nutritional supplements prescribed as part of cancer treatment.
• Cancer screening, which is health-funded and free through the national programmes.

What the NDIS can fund for a participant is the disability support they would need anyway, and the supports arising from permanent impairment once there is some.

Who to talk to

For NDIS access questions: the NDIA on 1800 800 110, and a local area coordinator or early childhood partner for the person’s region. An NDIS appeals advocate if a decision has gone against you.

For a participant whose circumstances have changed: their support coordinator, or the NDIA directly to request a plan reassessment. Treat it as urgent and say why — the NDIA has a priority pathway for significant unexpected deterioration in functional capacity where appropriate supports are not in place, with decisions in two to five business days.

For people over 65: My Aged Care on 1800 200 422.

For cancer itself: Cancer Council’s 13 11 20, free and staffed by cancer nurses. They also have practical and financial support information that goes well beyond anything we can offer.

For advocacy: disability advocacy organisations funded under the National Disability Advocacy Programme, and the NDIS Appeals programme for review matters.